Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

4.190 -0.030 (-0.71%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction. 
Via Benzinga
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024. 
Via Benzinga
Why GoodRx Holdings Stock Was Sinking This Week
The company is growing key fundamentals. However, the improvements weren't enough to impress the market. 
Via The Motley Fool
GoodRx (GDRX) Q3 2024 Earnings Call Transcript
GDRX earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
GoodRx Holdings Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
 
Via Benzinga
The Analyst Landscape: 7 Takes On GoodRx Holdings
 
Via Benzinga
Forecasting The Future: 13 Analyst Projections For GoodRx Holdings
 
Via Benzinga
Why GoodRx Surged Today
The prescription-drug upstart got an upgrade from Wall Street. 
Via The Motley Fool
The Latest Analyst Ratings For GoodRx Holdings
 
Via Benzinga
GoodRx (GDRX) Q2 2024 Earnings Call Transcript
GDRX earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
GoodRx Reports Q2 Earnings With Increased Prescription Revenue But Subscription Challenges
GoodRx reported Q2 revenue of $200.61M, a 6% YoY increase. Prescription transactions revenue rose 7%, driven by 8% growth in Monthly Active Consumers. The company expects FY 2024 revenue at the lower... 
Via Benzinga
MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
3 Lawsuit-Laden Stocks to Dump Before Problems Multiply
These stocks to sell face ongoing and past litigation, but that isn't the only sticking point in their long-term prospects. 
Via InvestorPlace
Market Correction Alert: Sell These 3 Tech Stocks While You Can
These tech stocks to sell combine shaky operational outlooks with underlying fundamental shakiness that don't bode well for the long-term. 
Via InvestorPlace
3 Stocks to Sell ASAP Before the June 27 Presidential Debate
These stocks to sell sit within politically sensitive sectors, making them too risky to hold as we approach election season. 
Via InvestorPlace
The 3 Most Undervalued Under-$10 Stocks to Buy in June 2024
These three, sub $10 stocks with enormous upside potential might just be your best investment nuggets this month. 
Via InvestorPlace
GoodRx Strengthens Core Business With New Initiatives, Analyst Upgrades On Potential Opportunities
GoodRx has been upgraded by RBC Capital Markets due to the growth potential from the Integrated Savings Program, direct contracting initiatives, and manufacturing solutions expansion. 
Via Benzinga
GoodRx Shares Soar Nearly 10% As New Partnership With Kroger Promises Big Savings
GoodRX shares surged nearly 10% Wednesday afternoon following the announcement of a new direct contracting agreement with Kroger Co. (NYSE:KR). 
Via Benzinga
NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
GoodRx (GDRX) Q1 2024 Earnings Call Transcript
GDRX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Change Healthcare Cyberattack: GoodRx Expects Low Single Digit Million-Dollar Impact In 2024
GoodRx's Q1 earnings: $0.08 EPS, sales hit $197.88 million, beating expectations fueled by prescription transactions and pharma solutions. Q2 forecast: ~$200 million revenue, optimistic 2024 outlook. 
Via Benzinga
GDRX Stock Earnings: GoodRx Holdings Beats EPS, Beats Revenue for Q1 2024
GDRX stock results show that GoodRx Holdings beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings
GoodRx Holdings Inc (NASDAQ: GDRX) got an upgrade last month from Wells Fargo analyst. 
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
Telemedicine GoodRx Has Potential To Excel, Close Valuation Gap By 2025, Analyst Says
Wells Fargo's upgrade of GoodRx Holdings. Analysts anticipate strong revenue visibility and EBITDA margins, setting the stage for potential stock outperformance in 2024-2025. 
Via Benzinga
Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling by around 50 points on Monday. Shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
These Analysts Increase Their Forecasts On GoodRx Following Q4 Earnings
GoodRx Holdings, Inc. (NASDAQ: GDRX) reported upbeat fourth-quarter FY23 results and issued first-quarter revenue guidance above estimates. 
Via Benzinga
Why GoodRx Stock Soared Today
The company beat Q4 estimates, announced a new share repurchase authorization, and issued strong guidance. 
Via The Motley Fool
GoodRx (GDRX) Q4 2023 Earnings Call Transcript
GDRX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Why Is Telemedicine Firm GoodRx's Shares Surging Today
GoodRx Holdings reported strong Q4 results and issued above-estimate revenue guidance for FY24. Revenue and adjusted EBITDA increased, company also announced new stock repurchase program. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.